AcelRx Pharmaceuticals Inc. (ACRX)

2.51
NASDAQ : Health Technology
Prev Close 2.48
Day Low/High 2.43 / 2.65
52 Wk Low/High 1.65 / 5.05
Avg Volume 2.79M
Exchange NASDAQ
Shares Outstanding 76.39M
Market Cap 189.46M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Insiders Seeing Green With ACRX At New 52-Week High

Insiders Seeing Green With ACRX At New 52-Week High

In trading on Monday, shares of AcelRx Pharmaceuticals Inc touched a new 52-week high of $5.03/share. That's a 224.52% rise, or $3.48 per share from the 52-week low of $1.55 set back on 10/19/2017.

It’s a Key Day for This Specialty Pharma Position

FDA review of AcelRx Pharma's DSUVIA should produce a significant reaction in the shares.

Stocks Under $10 Weekly Summary

We added to four positions during a rough week for small-cap names.

Stocks Under $10 Weekly Summary

We initiated a new position and added to a newer name during a mixed week for the portfolio.

Analyzing a Position’s Ups and Downs

There are several reasons to believe in AcelRx Pharmaceuticals’ recent rise.

Stocks Under $10 Weekly Summary

Last week was a frenetic one for the portfolio as we scaled into one name, added another to the fold, and booked some hefty profits in a cannabis stock.

Stocks Under $10 Weekly Summary

Last week we re-initiated a position in Aurora Cannabis, exited USA Technologies and added to our holdings in Del Frisco's Restaurant Group.

AcelRx Announces Date Of FDA Advisory Committee Meeting For DSUVIA™

AcelRx Announces Date Of FDA Advisory Committee Meeting For DSUVIA™

DSUVIA Advisory Committee meeting date set for October 12, 2018

Stocks Under $10 Weekly Summary

We added a starter a position in Parateum Corp. during a challenging week for the portfolio.

Stocks Under $10 Weekly Summary

We added 2 new positions last week as the portfolio finished the summer strong.

Stocks Under $10 Weekly Summary

Last week was a busy one for the portfolio as we exited 3 positions.

Stocks Under $10 Weekly Summary

There were several bright spots in the portfolio last week, including Habit Restaurants and USA Technologies.

Stocks Under $10 Weekly Summary

The portfolio had several big winners last week as shares of Habit Restaurants and Energy Recovery soared.

A Positive Reaction For These Two Companies Following Q2 Earnings

While ArcelRx Pharmaceuticals faces key milestones, I'm excited about Energy Recovery.

AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results

AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results

- European Commission approved DZUVEO (sufentanil sublingual tablet, 30 mcg) for the management of acute moderate-to-severe pain in adults in medically monitored settings

Stocks Under $10 Weekly Summary

We trimmed one position and added to another last week as smaller-cap stocks took a hit.

Stocks Under $10 Weekly Summary

During a week that showed little change for the major stock market indices, the portfolio had a number of outperformers.

Stocks Under $10 Weekly Summary

Similar to the Russell 2000 trading off last week so too did a number of our holdings, although there were bright spots as well.

Update and Target Change on Healthcare Holding

Winning position AcelRx recently announced a public offering.

Updates on 8 Portfolio Positions

A look at several of our positions over the past week.

Stocks Under $10 Weekly Summary

It was a challenging week for the portfolio amid continued trade and tariff concerns.

Stocks Under $10 Weekly Summary

It was a good week for the portfolio, as a large majority of positions outperformed the market.

Stocks Under $10 Weekly Summary

Last week, we initiated a position in Farmland Partners and trimmed our holdings in AcelRx Pharmaceuticals.

Trimming a Position on Strength

We will sell some of our AcelRx holdings as the stock moves through out current price target.

TheStreet Quant Rating: D- (Sell)